Bristol Erbitux Decision Will Follow Feb. 26 FDA Meeting
Bristol-Myers Squibb will decide whether to proceed with the Erbitux collaboration with ImClone after a Feb. 26 meeting with FDA
Bristol-Myers Squibb will decide whether to proceed with the Erbitux collaboration with ImClone after a Feb. 26 meeting with FDA